Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors

Michael A. Spinner, MD, Marcelo Fernandez Vina, PhD, Linda Elder, BA, Sally Arai, MD, Laura Johnston, MD, Everett Meyer, MD PhD, David Miklos, MD PhD, Lori Muffly, MD, Robert S. Negrin, MD, Judith Shizuru, MD PhD, Wen-Kai Weng, MD PhD, Ginna G. Laport, MD, Samuel Strober, MD, Robert Lowsky, MD, Andrew R. Rezvani, MD

Blood (2016) 128 (22): 4669.

https://doi.org/10.1182/blood.V128.22.4669.4669

Published: 2016

Journal Articles

A Phase I Study of Donor Regulatory T Cells As Treatment for Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Laura Johnston, MD, Randall Armstrong, Jeanette Baker, PhD, Bita Sahaf, Joanne Otani, Keri Tate, PhD, Cynthia Tudisco, Kevin Sheehan, PhD, Everett Meyer, MD PhD, David Miklos, MD PhD, Robert S. Negrin, MD

Blood (2016) 128 (22): 385.

https://doi.org/10.1182/blood.V128.22.385.385

Published: 2016

Journal Articles

Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation

Lori S. Muffly, MDMS, Kevin Sheehan, PhD, Randall Armstrong, Keri Tate, PhD, Cynthia Tudisco, Andrew R. Rezvani, MD, David Miklos, MD PhD, Sally Arai, MD, Judith Shizuru, MD PhD, Laura Johnston, Everett Meyer, MD PhD, Wen-Kai Weng, MD PhD, Ginna G. Laport, MD, Robert S Negrin, MD, Sam Strober, Robert Lowsky, MD

Blood (2016) 128 (22): 4615.

https://doi.org/10.1182/blood.V128.22.4615.4615

Published: 2016

Journal Articles

Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1

Blood (2016) 128 (22): LBA-6.

https://doi.org/10.1182/blood.V128.22.LBA-6.LBA-6

Published: 2016

Journal Articles

Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms

Blood (2015) 126 (23): 3232.

https://doi.org/10.1182/blood.V126.23.3232.3232

Published: 2015

Journal Articles

Chronic Graft-Versus-Host Disease Responds to Imatinib and Pre Transplant/Donor Anti-PDGFRA Antibodies Predict for Chronic Graft-Versus-Host Disease Development

George L. Chen, MD, Sally Arai, MD, Mary E.D. Flowers, MD, Joanne M Otani, RN, MSN, BS, Marc Coram, PhD, Alex McMillan, PhD, Judith A Shizuru, PhD, MD, Laura Johnston, MD, David Miklos, MD, PhD

Blood (2010) 116 (21): 2320.

https://doi.org/10.1182/blood.V116.21.2320.2320

Published: 2010

Journal Articles

Protein Microarrays Identify Elevated Allogeneic Antibodies In Association with Extensive Chronic Graft Versus Host Disease

John F. Tan, MD, George L. Chen, MD, Persis P. Wadia, PhD, Marc Coram, PhD, David Miklos, MD, PhD

Blood (2010) 116 (21): 2344.

https://doi.org/10.1182/blood.V116.21.2344.2344

Published: 2010

Journal Articles

Chronic Gvhd Global Severity According to NIH Consensus Criteria: Results From the Chronic Gvhd Consortium

Sally Arai, MD, Madan Jagasia, MD, MS, Mukta Arora, MD, David Miklos, MD, PhD, Xiaoyu Chai, MS, Barry Storer, PhD, Paul J. Martin, Corey Cutler, MD, MPH, FRCPC, Daniel J. Weisdorf, MD, Joseph Pidala, Jeanne Palmer, MD, Mary Flowers, MD, David Jacobsohn, MD, Paul A. Carpenter, Steven Z. Pavletic, MD, Georgia B. Vogelsang, MD, Stephanie J. Lee

Blood (2010) 116 (21): 220.

https://doi.org/10.1182/blood.V116.21.220.220

Published: 2010

Journal Articles

A Dose Escalation Trial of Imatinib for Steroid Dependent Chronic Graft-Versus-Host Disease with Anti-PDGFRA Antibody Analysis.

George L. Chen, MD, Sally Arai, MD, Mary E.D. Flowers, MD, Joanne Otani, RN, MSN, Ethan C. Cheng, Alex McMillan, PhD, Wen-Kai Weng, MD, PhD, Judith Shizuru, PhD, MD, Laura Johnston, MD, David Miklos, MD, PhD

Blood (2009) 114 (22): 3304.

https://doi.org/10.1182/blood.V114.22.3304.3304

Published: 2009

Journal Articles

Modeling Chronic Graft-Versus-Host-Disease: A New MHC-Matched Model of Late-Onset Scleroderma After Low-Dose Conditioning and Hematopoietic Cell Transplantation That Affects Only Male Recipients of Female Grafts.

Antonia MS Mueller, David Miklos, MD, PhD, Judith Shizuru, PhD, MD

Blood (2009) 114 (22): 3560.

https://doi.org/10.1182/blood.V114.22.3560.3560

Published: 2009

Journal Articles

Post Transplant Allogeneic Antibody Responses Form against Annexin 8

George L. Chen, M.D., Nilou Arden, PhD, David Miklos, MD, PhD

Blood (2008) 112 (11): 4605.

https://doi.org/10.1182/blood.V112.11.4605.4605

Published: 2008

Journal Articles

Composition and Persistence of Donor Cell Infiltrates in Host Target Organs Instigate the Development of Chronic Graft-Versus-Host Disease

Antonia MS Mueller, Jessica A Allen, David Miklos, MD, PhD, Karen Berry, Judith Shizuru, MD, PhD

Blood (2008) 112 (11): 3523.

https://doi.org/10.1182/blood.V112.11.3523.3523

Published: 2008

Journal Articles

Complete Donor Chimerism Predicts Molecular Remission in High Risk CLL Following Nonmyeloablative Transplantation.

Carol Jones, Renee Letzinger, James L. Zehnder, MD, David Miklos, MD, PhD

Blood (2008) 112 (11): 3283.

https://doi.org/10.1182/blood.V112.11.3283.3283

Published: 2008

Journal Articles

Rituximab Infusion Two Months after HCT Decreases Alloreactive B Cell Responses While Recipient Plasma Cells Persist.

Bi ta Sahaf, PhD, Julie R. Boiko, George Chen, MD, Kartoosh Heydari, MD, Sally Arai, MD, David Miklos, MD, PhD

Blood (2008) 112 (11): 2234.

https://doi.org/10.1182/blood.V112.11.2234.2234

Published: 2008

Journal Articles

Identification of a Homeobox-Like Protein Immune Response in Bone Marrow Transplant Patients

Nilou Arden, PhD, George L. Chen, M.D., David Miklos, MD, PhD

Blood (2008) 112 (11): 4856.

https://doi.org/10.1182/blood.V112.11.4856.4856

Published: 2008

Journal Articles

Rituximab Infusion after Allogeneic HCT Delays B Cell Reconstitution and Alloimmunity.

Bita Sahaf, PhD, Kartoosh Heydari, MD, George Chen, MD, David Miklos, MD, PhD

Blood (2007) 110 (11): 2982.

https://doi.org/10.1182/blood.V110.11.2982.2982

Published: 2007

Journal Articles

Donor T Cells from B Cell Deficient Mice Inhibit B Cell Development in Normal Recipients after Hematopoietic Cell Transplantation.

Antonia M.S. Mueller, MD, Jessica A. Allen, David Miklos, MD PhD, Judith A. Shizuru, MD PhD

Blood (2007) 110 (11): 3265.

https://doi.org/10.1182/blood.V110.11.3265.3265

Published: 2007

Journal Articles

Comparison of Three Minor-Mismatched Mouse Models of Chronic Graft Versus Host Disease.

Antonia M.S. Mueller, MD, Jessica A. Allen, BA, David Miklos, MD PhD, Judith A. Shizuru, MD PhD

Blood (2007) 110 (11): 3237.

https://doi.org/10.1182/blood.V110.11.3237.3237

Published: 2007

Journal Articles

Cytokine Induced Killer (CIK) Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation.

Ginna G. Laport, MD, Kevin Sheehan, PhD, Robert Lowsky, MD, Judith A. Shizuru, MD,PhD, Keith Stockerl-Goldstein, MD, Laura J. Johnston, MD, David Miklos, MD,PhD, Sally Arai, MD, Jeanette Baker, Robert S. Negrin, MD

Blood (2006) 108 (11): 412.

https://doi.org/10.1182/blood.V108.11.412.412

Published: 2006

Journal Articles

Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.

Corey Cutler, MD MPH FRCPC, Shuli Li, MS, Haesook T. Kim, PhD, Edwin Alyea, MD, Vincent Ho, MD, Stephanie J. Lee, MD MPH, David C. Fisher, MD, Robert Schlossman, MD, David Miklos, MD PhD, Stephen Sonis, DMD DMSc, Robert Soiffer, MD, Joseph H. Antin, MD

Blood (2004) 104 (11): 1227.

https://doi.org/10.1182/blood.V104.11.1227.1227

Published: 2004

NARROW

Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors

A Phase I Study of Donor Regulatory T Cells As Treatment for Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation

Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1

Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms

Chronic Graft-Versus-Host Disease Responds to Imatinib and Pre Transplant/Donor Anti-PDGFRA Antibodies Predict for Chronic Graft-Versus-Host Disease Development

Protein Microarrays Identify Elevated Allogeneic Antibodies In Association with Extensive Chronic Graft Versus Host Disease

Chronic Gvhd Global Severity According to NIH Consensus Criteria: Results From the Chronic Gvhd Consortium

A Dose Escalation Trial of Imatinib for Steroid Dependent Chronic Graft-Versus-Host Disease with Anti-PDGFRA Antibody Analysis.

Modeling Chronic Graft-Versus-Host-Disease: A New MHC-Matched Model of Late-Onset Scleroderma After Low-Dose Conditioning and Hematopoietic Cell Transplantation That Affects Only Male Recipients of Female Grafts.

Post Transplant Allogeneic Antibody Responses Form against Annexin 8

Composition and Persistence of Donor Cell Infiltrates in Host Target Organs Instigate the Development of Chronic Graft-Versus-Host Disease

Complete Donor Chimerism Predicts Molecular Remission in High Risk CLL Following Nonmyeloablative Transplantation.

Rituximab Infusion Two Months after HCT Decreases Alloreactive B Cell Responses While Recipient Plasma Cells Persist.

Identification of a Homeobox-Like Protein Immune Response in Bone Marrow Transplant Patients

Rituximab Infusion after Allogeneic HCT Delays B Cell Reconstitution and Alloimmunity.

Donor T Cells from B Cell Deficient Mice Inhibit B Cell Development in Normal Recipients after Hematopoietic Cell Transplantation.

Comparison of Three Minor-Mismatched Mouse Models of Chronic Graft Versus Host Disease.

Cytokine Induced Killer (CIK) Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation.

Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only